News
WATCH: Channel Five's Documentary 'Teacher with Tourette's: Cursing in the classroom'
Five years ago, Natalie, a teacher who lives with Tourette's, started working with the University of Nottingham to find out how electrical pulses can control tics, often experienced by those living with Tourette’s. She explained: "The first time I took part in the trial, I remember being quite emotional about it because I felt this emptiness and relaxed state that I hadn't, or couldn't remember, feeling." Natalie returned to the university to try the new device from Neupulse that has been designed to help those with Tourette's. Professor Stephen Jackson, who led the research behind the device, explained: "What Natalie is getting is two minutes of stimulation at a given frequency, with a minute's break, followed by another two minutes with a minute's break. She's getting intermittent stimulation." Upon trying the device, Natalie's tics subsided and allowed her to enter the university's library, somewhere she had previously been worried about going into.
Learn more
Neupulse expands their team
Neupulse is delighted to welcome two new members to our team: Ciara McCready as a Research Assistant and Claire Hall as our Quality & Regulatory Manager. Ciara McCready joins us with experience as a Psychology Assistant in the Neurotherapeutics Ltd clinical trial, where she worked with participants with Tourette’s Syndrome to collect and analyse data on the use of wearable devices. With her Masters in Developmental Psychology from the University of Nottingham, Ciara will conduct research to support the development of our medical wearable device. We are also excited to have Claire Hall on board as our Quality & Regulatory Manager. She brings with her over 19 years of experience in quality management practices and regulatory affairs in the medical device and pharmaceutical industries. Claire will be responsible for our Quality Management System and ISO 13485 certification, ensuring we meet regulatory requirements and maintain the highest standards of quality. Media contact: enquiries@neupulse.co.uk
Learn more
Clinical trial investigating the effects of median nerve stimulation on Tourette syndrome: Results
We are excited to share the results of the UK-wide double-blind sham-controlled clinical trial of the Neupulse device for suppressing tics in Tourette syndrome. The trial was run by the University of Nottingham, conducted between 18th March 2022 and 5th of March 2023, sponsored by Nottingham University Hospitals NHS Trust. The aim of the trial was to evaluate the effectiveness of the Neupulse device in reducing the severity and frequency of tics in individuals with Tourette Syndrome. A total of 121 participants took part in the study and went on to receive either active or sham stimulation for 10min a day for 4 weeks. The results of the study revealed that people who received active stimulation experienced a significant reduction in the severity and frequency of their tics. On average, they saw a reduction in tic frequency of more than 25% while they received stimulation. After using the device for 4 weeks, people who received active stimulation experienced a reduction in their tic severity of more than 35%. In total, 59% of the people who received active stimulation experienced a reduction in tic severity of at least 25% compared to baseline. We would like to thank all the participants who participated in the clinical trial and made it a success. These positive results will help start of the development of a commercial medical device, that will run for the next 18 months. We hope to obtain regulatory approval for a commercial device by 2025 and have a device available by 2026. Thank you for your continued support and interest in our work. Media contact: enquiries@neupulse.co.uk
Learn more
Neupulse strengthens their executive team
Neupulse is excited to announce that it has recruited 2 new key executives to their senior management team. Paul Cable, Neupulse’s current Chief Operating Officer, has been promoted to Chief Executive Officer. Paul has been with the Company since inception, and has been instrumental in leading the Neupulse team to achieving its milestones to date. Paul has over 30 years of global management experience in the MedTech industry, and has a unique ability to steer cross-functional teams to success across the entire life cycle of developing medical devices and bringing them to market. ‘It is a privilege to lead Neupulse and work with such a talented, driven team to achieve our goal of becoming the first non-invasive, game-changing treatment option for individuals with Tourette’s Syndrome around the world.’ Paul Cable, Chief Executive Officer Also joining Neupulse as its Chief Technology Officer is Doctor David Moser. David is a Chartered Engineer and Visiting Professor of Engineering at the University of Southampton, with a PhD in Biomedical Engineering and over 17 years of experience developing wearable assistive technologies and medical devices. David was formerly Director of Research and Technology at Blatchford, where he led the development of some of the world’s most advanced, award-winning prosthetics, including the RAEng MacRobert Award in 2016, and the US Medical Device Excellence Award in 2017. David holds over 25 patents and has published extensively in the areas of prosthetics, body interface technologies, robotics, physical rehabilitation, and digital health. As CTO, David will head up Neupulse’s Technology and New Product Development team. Media contact: enquiries@neupulse.co.uk
Learn more
Lewis Capaldi visits the Neupulse office to try out our wearable wrist device
What an incredible morning! Our team at Neupulse was honored to host Lewis Capaldi, who came to visit us in Nottingham to try out our wearable device for treating Tourette Syndrome. Lewis was able to experience first-hand the benefits of our device and he shared that he felt a significant reduction in his symptoms while using it. He was also very kind with our team, and took the time to take some pictures. We want to thank Lewis for his support and for being such a great ambassador for those living with Tourette's. Remember, you can sign up to get the latest updates on our development of our device and be the first to know when it is available to purchase. #Tourettesyndrome #TouretteTreatment #Neupulse #LewisCapaldi
Learn more
Neupulse raises £918k in a second round of funding
Neupulse, a University of Nottingham spin out, raised £918k to give people with Tourette’s Syndrome the option to control tics through a wearable. Neupulse has completed a second round of funding in December 2022. Funds have been raised from existing investors and groups of HNW individuals from around the world The investment will start the development of the commercially available wearable for use by individuals with Tourettes Syndrome to stop tics. ‘This is an exciting time for the company as move forward to the next stage of our development by starting to design the wearable that will bring choice to thousands of individuals that have Tourettes Syndrome’ Paul Cable, Chief Operating Officer Since incorporation in March 2021 the company has completed several significant milestones including development of a prototype device for use in a double blinded study, completed the recruitment and are working on analysing the data, the results of the double blinded study, these will be published in Q2 2023 and developed an App to support individuals in recording their tics will go to marketing evaluation in Q1 2023. Tourette's syndrome is a condition that causes a person to make involuntary sounds and movements called tics. It usually starts during childhood, but the tics and other symptoms usually improve after several years and sometimes go away completely. There's no cure for Tourette's syndrome, but drug or CBiT treatment can help manage symptoms.
Learn more
Natalie Davidson tries the Neupulse device during the filming of Channel 5 TV documentary
Natalie Davidson (@tourettesteach), who is filming Part 2 of the documentary ‘The Teacher with Tourette’s’ with @channel5_tv, came to Nottingham to try the wearable wrist device developed by Neupulse and used in a clinical trial that is now underway. The clinical trial is being run by Neupulse with Nottingham University Hospitals (NUH) and University of Nottingham as partners and does not accept any more participants.
Learn more
Clinical trial investigating the effects of median nerve stimulation on Tourette syndrome is now underway
The clinical trial investigating the effects of median nerve stimulation on Tourette syndrome and associated symptoms has completed recruitment and all participants are now in the ‘follow-up period’, in which participants health is monitored for 6 months. The results from the trial will be published in 2023. We thank everybody who showed interest in taking part in the trial and we thank Tourette’s Action for their help with recruitment and continuous support.
Learn more
Response by Tourette's Action to the Channel 4 documentary 'Britain's Tourettes Mystery'
Following the program “Britain’s Tourette’s Mystery” that was aired on C4 last week which contained many inaccurate and misleading facts, Tourette’s Action UK has issues the following press release
Learn more